Biomx Financials

PHGE Stock  USD 0.73  0.02  2.82%   
Based on the key measurements obtained from Biomx's financial statements, Biomx Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At present, Biomx's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Other Liabilities is expected to grow to about 2.6 M, whereas Total Current Liabilities is forecasted to decline to about 6.4 M. Key indicators impacting Biomx's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin69.6473.3025
Notably Down
Slightly volatile
Debt Equity Ratio4.043.8471
Sufficiently Up
Slightly volatile
Current Ratio1.51.5777
Notably Down
Very volatile
The essential information of the day-to-day investment outlook for Biomx includes many different criteria found on its balance sheet. An individual investor should monitor Biomx's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Biomx.

Net Income

(27.48 Million)

  
Please note, the presentation of Biomx's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomx's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomx's management manipulating its earnings.

Biomx Stock Summary

Biomx competes with ZyVersa Therapeutics, Immix Biopharma, Cns Pharmaceuticals, and Sonnet Biotherapeutics. BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. Biomx operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 103 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNYSE MKT Exchange
ISINUS09090D1037
CUSIP09090D103 15957A108 09090D301
LocationNew York; U.S.A
Business Address22 Einstein Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.biomx.com
Phone972 7 2394 2377
CurrencyUSD - US Dollar

Biomx Key Financial Ratios

Biomx Key Balance Sheet Accounts

201920202021202220232024 (projected)
Other Liab585K701K215K2.2M2.5M2.6M
Net Tangible Assets42.8M84.5M57.5M46.0M52.9M53.3M
Retained Earnings(42.2M)(72.3M)(108.5M)(136.8M)(163.0M)(154.8M)
Net Receivables50K276K(108K)567K574K602.7K
Net Invested Capital84.5M57.5M61.9M35.9M14.3M13.6M
Net Working Capital78.3M53.5M55.6M28.9M6.5M6.1M

Biomx Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense64K7K699K2.1M2.4M2.5M
Operating Income(22.2M)(30.3M)35.5M(27.2M)(27.7M)(26.3M)
Ebit(22.2M)(30.1M)(35.5M)(26.2M)(23.7M)(24.9M)
Research Development13.5M20.9M22.7M16.2M19.0M14.7M
Income Before Tax(20.6M)(30.1M)(36.2M)(28.3M)(26.1M)(27.5M)
Net Income(18.9M)(29.9M)(36.2M)(28.3M)(26.2M)(27.5M)
Tax Provision0.03K67K65K61K44.2K
Net Interest Income1.2M518K(620K)(1.6M)(1.7M)(1.6M)
Interest Income921K641K86K464K792K506.3K
Ebitda(22.4M)(27.9M)(32.9M)(23.7M)(22.8M)(24.0M)
Income Tax Expense(1.6M)(172K)67K65K23K24.2K

Biomx Key Cash Accounts

201920202021202220232024 (projected)
Investments21.1M(9.8M)16.2M(2.1M)3.4M3.6M
Change To Netincome634K3.0M2.8M670K770.5K1.5M

Biomx Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biomx's current stock value. Our valuation model uses many indicators to compare Biomx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomx competition to find correlations between indicators driving Biomx's intrinsic value. More Info.
Biomx Inc is regarded fifth in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . At present, Biomx's Return On Equity is projected to drop slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Biomx by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Biomx Inc Systematic Risk

Biomx's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biomx volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Biomx Inc correlated with the market. If Beta is less than 0 Biomx generally moves in the opposite direction as compared to the market. If Biomx Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biomx Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biomx is generally in the same direction as the market. If Beta > 1 Biomx moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Biomx Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomx's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biomx growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0125

At present, Biomx's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Biomx December 2, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Biomx help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biomx Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biomx Inc based on widely used predictive technical indicators. In general, we focus on analyzing Biomx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biomx's daily price indicators and compare them against related drivers.

Complementary Tools for Biomx Stock analysis

When running Biomx's price analysis, check to measure Biomx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomx is operating at the current time. Most of Biomx's value examination focuses on studying past and present price action to predict the probability of Biomx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomx's price. Additionally, you may evaluate how the addition of Biomx to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamental Analysis
View fundamental data based on most recent published financial statements